Oral Insulin: Potential First Line Therapy for Type 2 Diabetics
As a first line therapy, oral insulin has the potential to slow the progression of Type 2 diabetes by improving the longevity of beta cells
- Bedtime dosing in Type 2 diabetics with oral insulin
- Suppresses overnight-fasting insulin secretion in Type 2 diabetic patients
- May improve fasting hepatic insulin sensitivity, evidenced by unchanged fasting glycemia with reduced fasting insulinemia
- The physiologic actions of oral insulin are exerted far longer (ɴ hrs) than predicted by its rapid systemic pharmacokinetics (Cmax @ 25 min)
- Oral insulin at bedtime may spare ß-cell function